IDEA TO CLINIC
Live / Applied — First extension granted (statement of use) (as of 25 Feb 2026)
What this means for you
Not registered yet, but its 25 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98667074
- Mark type
- Stylized text
- Filed
- 25 Jul 2024
- Published for opposition
- 01 Jul 2025
- Attorney of record
- Susan M. Natland
Goods and services
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals, biological preparations, chemical preparations, and reagents for others; biomanufacturing for others, namely, manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; biomanufacturing platform for others in the nature of custom manufacturing, custom biomanufacturing manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; consulting services in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; custom processing and manufacture of vectors, cells and proteins for use in the field of biotechnology
- Class 042 — Scientific and technological services: Scientific research, development, and consulting services in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; Scientific research in the field of genetic engineering; biotechnology research and development; scientific, pharmaceutical, and medical research services relating to biological treatment and bioproduction; provision of information in the field of scientific research and development of biopharmaceuticals that are manufactured using biological treatment and bioproduction platforms; development of new technology for others in the field of biotechnology, biomanufacturing, and pharmaceuticals; new product design services; biotechnology design services in the field of the creation of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; preparation of reports in the nature of providing information about scientific research in the field of biomanufacturing and manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and protein
Owner
- NATIONAL RESILIENCE, LLC, BLUE ASH, OH, US
- National Resilience, Inc., San Diego, CA, US
- National Resilience, Inc., San Diego, CA, US
Prosecution history
- 26 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Feb 2026 — SOU EXTENSION 1 GRANTED
- 25 Feb 2026 — SOU EXTENSION 1 FILED
- 25 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 11 Feb 2026 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 11 Feb 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 11 Feb 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 11 Feb 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 11 Feb 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 26 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Jul 2025 — PUBLISHED FOR OPPOSITION
- 25 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 29 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 May 2025 — EXAMINER'S AMENDMENT ENTERED